Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16).
Richard F PollockWilliam J ValentineSteven P MarsoAndreas AndersenJens GundgaardNino HallénDeniz TutkunkardasElizabeth A MagnusonJohn B Busenull nullPublished in: Applied health economics and health policy (2020)
Our long-term modeling analysis suggested that degludec was cost effective (from the perspective of NHS England) versus glargine U100 in basal-bolus regimens for patients with T2D at high CV risk. Our findings raise important questions regarding how to model the health economics of diabetes therapies.